Ruiz‐Villaverde R, et al. - In this retrospective study involving patients with moderate‐to‐severe plaque psoriasis, researchers analyzed drug survival and discontinuation rates for secukinumab treatment under real‐world conditions. Participants in the study were patients treated in the dermatology department of five Spanish medical centers between 2015 and 2019. A total of 171 treated patients were retrospectively recorded and analyzed for 152 weeks. Findings revealed that the discontinuation rate in the PsA group was 14.10% compared with 12.10% among those who had no PsA. Data reported that the mean survival time of discontinuation was 63 weeks for PsA compared with 65 weeks for no PsA. In all patient profiles, the mean survival time of patients in secukinumab treatment was similar and better than the data found in clinical trials and real‐life studies.